These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21993974)

  • 21. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
    Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
    Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
    ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
    Mochizuki I; Takiuchi H; Ikejiri K; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Takahashi Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Matsubara Y; Sugihara K
    Br J Cancer; 2012 Mar; 106(7):1268-73. PubMed ID: 22415232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
    Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
    Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer.
    Chen PH; Jhou HJ; Chung CH; Wu YY; Huang TC; Lee CH; Chien WC; Chen JH
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676634
    [No Abstract]   [Full Text] [Related]  

  • 28. UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.
    Smith R; Wickerham DL; Wieand HS; Colangelo L; Mamounas EP
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):44-7. PubMed ID: 10442360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
    Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
    PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
    Tsuchiya T; Sadahiro S; Sasaki K; Kondo K; Katsumata K; Nishimura G; Kakeji Y; Baba H; Morita T; Koda K; Sato S; Matsuoka J; Yamaguchi Y; Usuki H; Hamada C; Kodaira S; Saji S
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1253-61. PubMed ID: 24744162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
    Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
    Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metronomic chemotherapy with tegafur-uracil following radical resection in stage II colorectal cancer.
    Chen TC; Jeng YM; Liang JT
    J Formos Med Assoc; 2021 May; 120(5):1194-1201. PubMed ID: 33023787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer.
    Kasumi F; Yoshimoto M; Uchino J; Abe R; Nomura Y; Sugimachi K; Nakazato H; Abe O
    Oncology; 2003; 64(2):146-53. PubMed ID: 12566912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.
    Cellier P; Leduc B; Martin L; Vié B; Chevelle C; Vendrely V; Salemkour A; Carrie C; Calais G; Burtin P; Campion L; Boisdron-Celle M; Morel A; Berger V; Gamelin E
    BMC Cancer; 2011 Mar; 11():98. PubMed ID: 21410976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: a preliminary study.
    Tokunaga Y; Hata K; Nishitai R; Kaganoi J; Nanbu H; Ohsumi K
    J Surg Oncol; 1997 Sep; 66(1):45-50. PubMed ID: 9290692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
    Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
    Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
    PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
    Tsunoda A; Nakao K; Tsunoda Y; Watanabe M; Matsui N
    Int J Clin Oncol; 2010 Apr; 15(2):153-60. PubMed ID: 20191299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.